Xiaobin Liu Selected Research

p80(NPM-ALK) protein

9/2011	Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOS.
4/2009	Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xiaobin Liu Research Topics

Disease

18	Neoplasms (Cancer) 01/2022 - 11/2007
10	T-Cell Lymphoma (Lymphoma, T Cell) 01/2022 - 06/2006
6	Lymphoma (Lymphomas) 01/2013 - 02/2008
5	Membranous Glomerulonephritis (Membranous Nephropathy) 03/2022 - 01/2017
5	Asthma (Bronchial Asthma) 01/2018 - 01/2017
4	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 10/2019 - 01/2016
4	Breast Neoplasms (Breast Cancer) 01/2019 - 11/2017
4	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 03/2014 - 02/2008
3	Lung Injury 02/2021 - 01/2019
3	Ischemia 01/2019 - 04/2015
3	Infections 01/2017 - 04/2015
2	Carcinoma (Carcinomatosis) 11/2022 - 07/2022
2	Carcinogenesis 01/2022 - 06/2006
2	Acute Kidney Injury (Acute Renal Failure) 08/2021 - 01/2021
2	Thrombosis (Thrombus) 01/2021 - 01/2006
2	Burns 01/2021 - 01/2021
2	Chronic Kidney Failure (Chronic Renal Failure) 01/2021 - 07/2015
2	Wounds and Injuries (Trauma) 01/2021 - 01/2021
2	Proteinuria 11/2019 - 01/2017
2	Ventilator-Induced Lung Injury 11/2019 - 01/2019
2	Hypoglycemia (Reactive Hypoglycemia) 05/2017 - 08/2015
2	Hypoxia (Hypoxemia) 05/2017 - 08/2015
2	B-Cell Lymphoma (Lymphoma, B Cell) 01/2013 - 09/2005
2	Hyperglycemia 02/2012 - 07/2011
1	Glioma (Gliomas) 01/2022
1	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 11/2021
1	Ischemic Stroke 11/2021
1	Inflammation (Inflammations) 11/2021
1	Kidney Diseases (Kidney Disease) 10/2021
1	Diabetes Complications 06/2021
1	Schizophrenia (Dementia Praecox) 05/2021
1	Necrosis 02/2021
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 02/2021
1	Pneumonia (Pneumonitis) 02/2021
1	Fibrosis (Cirrhosis) 02/2021
1	Edema (Dropsy) 02/2021

Drug/Important Bio-Agent (IBA)

8	Anaplastic Lymphoma KinaseIBA 01/2022 - 06/2006
7	Phosphotransferases (Kinase)IBA 01/2022 - 02/2008
6	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2008
6	CytokinesIBA 02/2021 - 02/2008
5	OzoneIBA 01/2018 - 01/2017
4	Phospholipase A2 ReceptorsIBA 01/2022 - 01/2017
4	Glucose (Dextrose)FDA LinkGeneric 11/2021 - 01/2013
4	Mechanistic Target of Rapamycin Complex 1IBA 12/2013 - 02/2008
3	AntibodiesIBA 03/2022 - 08/2009
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2022 - 11/2007
3	NucleophosminIBA 01/2022 - 04/2009
3	Oxygen (Dioxygen)IBA 11/2021 - 04/2015
3	Messenger RNA (mRNA)IBA 01/2021 - 12/2008
3	EnzymesIBA 05/2020 - 01/2013
3	Transcription Factors (Transcription Factor)IBA 01/2018 - 07/2011
3	Membrane Proteins (Integral Membrane Proteins)IBA 03/2014 - 12/2008
3	Interleukin-2 (IL2)IBA 12/2013 - 02/2008
3	Interleukin-10 (Interleukin 10)IBA 12/2013 - 06/2006
2	CollagenIBA 01/2022 - 01/2021
2	Immunoglobulin G (IgG)IBA 01/2022 - 11/2019
2	DesminIBA 01/2022 - 07/2015
2	Biological ProductsIBA 01/2022 - 02/2008
2	LipopolysaccharidesIBA 02/2021 - 01/2021
2	Therapeutic UsesIBA 02/2021 - 01/2021
2	Serum AlbuminIBA 11/2019 - 01/2017
2	Agammaglobulinaemia Tyrosine KinaseIBA 10/2019 - 01/2019
2	Neurokinin-1 Receptors (Neurokinin 1 Receptor)IBA 01/2019 - 01/2019
2	ibrutinibIBA 01/2019 - 01/2016
2	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2019 - 05/2017
2	Pyruvate KinaseIBA 01/2018 - 11/2017
2	Particulate MatterIBA 12/2017 - 01/2017
2	CreatinineIBA 06/2017 - 01/2017
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2014 - 09/2009
2	Sirolimus (Rapamycin)FDA Link 01/2013 - 01/2011
2	Insulin (Novolin)FDA Link 02/2012 - 07/2011
2	Streptozocin (Streptozotocin)FDA Link 02/2012 - 07/2011
2	GastrinsIBA 02/2012 - 07/2011
2	Epidermal Growth Factor (EGF)IBA 02/2012 - 07/2011
2	p80(NPM-ALK) proteinIBA 09/2011 - 04/2009
2	Transforming Growth Factor beta (TGF-beta)IBA 08/2008 - 06/2006
1	Galectin 3 (LGALS3)IBA 03/2022
1	EuropiumIBA 03/2022
1	CalponinsIBA 01/2022
1	Calmodulin-Binding Proteins (Caldesmon)IBA 01/2022
1	Circular RNAIBA 01/2022
1	AutoantigensIBA 01/2022
1	SynaptophysinIBA 01/2022
1	Competitive Endogenous RNAIBA 11/2021
1	Long Noncoding RNAIBA 11/2021
1	AutoantibodiesIBA 10/2021
1	Monoclonal AntibodiesIBA 08/2021
1	Receptor for Advanced Glycation End ProductsIBA 06/2021
1	Advanced Glycation End ProductsIBA 06/2021
1	ErbB Receptors (EGF Receptor)IBA 06/2021
1	NeuropeptidesIBA 05/2021
1	Hematoxylin (Haematoxylon)IBA 02/2021
1	Small Interfering RNA (siRNA)IBA 02/2021
1	Eosine Yellowish-(YS) (Eosin)IBA 02/2021
1	EndotoxinsIBA 02/2021
1	Myosin Type IIIBA 02/2021

Therapy/Procedure

8	Therapeutics 01/2019 - 09/2005
3	Renal Dialysis (Hemodialysis) 01/2021 - 07/2015
2	Induction Chemotherapy 11/2022 - 07/2022
1	Transplantation 02/2021